GlassScriptPhysician profile
Lyad Gozal
NPI 1386760346
$9,956.77
in general payments reported to CMS, 2019-2025
24 companies · $2,939 in 2025
The $2,939 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $314 · 2021: $650 · 2022: $1,141 · 2023: $2,278 · 2024: $2,345 · 2025: $2,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,463 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,463.44 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,551.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,296.36 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,107.22 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,006.57 | 2019-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $999.00 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $979.40 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $898.58 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $312.78 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $293.41 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $274.62 | 2022-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $251.28 | 2024-2025 | Cobenfy |
| Allergan, INC. | $211.59 | 2019-2020 | |
| Indivior INC. | $198.25 | 2022-2024 | Perseris |
| Tris Pharma INC | $92.84 | 2024-2025 | Onyda Xr, Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $78.27 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $73.33 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.20 | 2021 | |
| Noven Therapeutics, LLC | $58.02 | 2021-2024 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $45.65 | 2021 | |
| Axsome Therapeutics, INC. | $43.13 | 2024-2025 | Auvelity |
| Adlon Therapeutics L.P. | $40.99 | 2021 | |
| Shire North American Group INC | $33.74 | 2019 | |
| Corium, LLC | $25.83 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyad Gozal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.